EAM
BCAB icon

Eventide Asset Management’s BioAtla BCAB Stock Holding History

Eventide Asset Management’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,900
Closed -$6.12M – 146
2022
Q3 		$6.12M Buy
+15,900
New +$5.2M 0.12% 117

Other funds holding BCAB

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Eventide Asset Management's BCAB Position: Q4 2022 in Review

Eventide Asset Management sold out of BioAtla (BCAB) in Q4 2022, closing a stake of 15,900 shares — an estimated $6.12M sold.

Eventide Asset Management first reported a position in BCAB in Q3 2022 and held it in 1 quarter. The position peaked at $6.12M in Q3 2022. 91 funds tracked by Wall St. Rank hold BCAB as of Q4 2022.

  • Eventide Asset Management reported no remaining BioAtla position as of Q4 2022 after selling out during the quarter.
  • Eventide Asset Management sold 15,900 BioAtla shares in Q4 2022, an estimated $6.12M.
  • Eventide Asset Management first reported a position in BioAtla in Q3 2022 and held it in 1 quarter.
  • Eventide Asset Management's BioAtla position peaked at $6.12M in Q3 2022.
  • 91 funds tracked by Wall St. Rank held BioAtla as of Q4 2022.

Based on Eventide Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.